Temozolomide (TMZ) is commonly used in glioma chemotherapy. However, a great clinical
challenge for TMZ is chemoresistance. H19 transcripts are recognized as long noncoding …

Background Recent findings around long noncoding RNAs (lncRNAs) have opened novel
areas of research around their prospective use in overcoming chemoresistance. Herein, we …

Glioblastoma multiforme (GBM) is a type of malignant carcinoma found in the brain. Its high
frequency of occurrence and poor survival rate have garnered much research attention in …

Temozolomide (TMZ) is widely used for glioma therapy in the clinic. Currently, the
development of TMZ resistance has largely led to poor prognosis. However, very little is …

Resistance to temolozomide (TMZ), the standard chemotherapy agent for treating
glioblastomas (GBM), is a major clinical problem for patients with GBM. Recently, long …

Background Although the incidence of glioma is relatively low, it is the most malignant tumor
of the central nervous system. The prognosis of high-grade glioma patient is very poor due …

Background Despite the development of new treatment protocols for glioblastoma (GBM),
temozolomide (TMZ) resistance remains a primary hindrance. Previous studies, including …

Background Accumulating evidence shows that long noncoding RNAs (lncRNAs) are
important regulator molecules involved in diverse biological processes. Acquired drug …

Background Our previous studies have indicated that miR-198 reduces cellular
methylguanine DNA methyltransferase (MGMT) levels to enhance temozolomide sensitivity …

The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major
burden for patients suffering from glioma. Recently, studies have demonstrated that micro …